Newland Pharmaceutical Co., Ltd. Class A

Newland Pharmaceutical Co., Ltd. Class A

SSZSE:301277
8.52
CNY
-0.04
(-0.47%)
0.23EPS
44.13P/E
4.11BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.02
1.39
1.48
1.75
2.08
1.67
1.84
1.72
1.87
Basic EPS, GAAP
0.1
0.37
0.4
0.39
0.44
0.41
0.44
0.31
0.24
Free Cash Flow per Basic Share
-0.04
0.1
0.11
0.08
0.03
0.42
0.04
0.04
- -
Dividend per Share
0.02
0.01
0.19
0.12
0.02
0.17
0.2
0.29
- -
Book Value per Share
1.34
0.66
1.07
1.37
3.46
3.69
3.93
3.96
3.92
Tangible Book Value per Share
1.2
0.52
0.93
1.23
3.36
3.6
3.84
3.83
3.8
Basic Weighted Avg Shares
290
292
293
294
302
390
395
391
392
Sales/Revenue/Turnover
295
407
433
514
627
651
726
672
734
Operating Margin (%)
9.52
28.86
33.91
29.26
23.79
24.64
26.34
19.83
15.91
Depreciation Expense
15
16
18
21
24
31
38
55
- -
Net Income, GAAP
29
109
118
115
132
159
174
121
93
Effective Tax Rate (%)
13.26
13.47
13.8
12.97
7.82
13.23
12.33
10.48
10.53
Profit Margin (%)
9.69
26.85
27.35
22.38
21.09
24.4
23.9
18.03
12.68
Working Capital
154
-12
91
180
1,031
1,017
978
896
900
LT Debt
- -
- -
20
30
3
1
2
3
1
Total Equity
391
191
313
406
1,359
1,449
1,543
1,551
1,536
Return on Invested Capital (%)
- -
31.36
37.94
26.92
14.52
11.39
11.73
7.85
6.07
Return on Capital (%)
- -
38.04
41.31
30.18
14.68
11.42
11.63
7.9
6.2
Return on Common Equity (%)
- -
37.51
46.93
32.12
15.05
11.34
11.61
7.84
6.11

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
392
392
392
Market Capitalization
4,619
3,431
4,105

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,106
1,046
1,051
Cash, Cash Equivalents & STI
666
619
663
Accounts Receivable, Net
142
171
142
Inventories
66
88
89
Total Current Liabilities
174
160
152
Payables & Accruals
- -
- -
- -
ST Debt
3
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
55.55%
0.52%
Free Cash Flow
- -
327.22%
-2.63%
Net Income, GAAP
- -
2.27%
-30.17%
Sales/Revenue/Turnover
- -
9.73%
-7.44%
Total Cash Common Dividend
- -
166.11%
40%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
185
212
140
189
726
2025
220
139
- -
191
672
2026
207
190
146
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.14
0.08
0.08
0.44
2025
0.14
0.05
- -
0.07
0.31
2026
0.09
0.06
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.2
2025
- -
- -
- -
- -
0.29
2026
- -
- -
- -
- -
- -

Company Description

CEO
Lu Wei Zhang
Full Time Employees
981
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Changge China
IPO Date
Nov 16, 2022
Business
Newland Pharmaceutical Co., Ltd. is a China-based pharmaceutical manufacturing company engaged in the research, development, production, and commercial distribution of chiral pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished dosage formulations, and contract development and manufacturing organization (CDMO) services. Founded in 2005 and headquartered in Changge, Henan Province, China, the company operates across the healthcare and specialty chemical sectors. The company's core operations are structured into three main segments: Pharmaceutical Intermediates, Active Pharmaceutical Ingredients, and Formulations and CDMO Services. Its Pharmaceutical Intermediates segment specializes in chiral chemical compounds and key antibiotic building blocks, comprising D-p-hydroxyphenylglycine (D-acid), D-p-hydroxyphenylglycine methyl ester, D-p-hydroxyphenylglycine potassium Dane salt, and glyoxylic acid utilized primarily in the synthesis of semi-synthetic penicillins and cephalosporins such as amoxicillin, cefprozil, cefadroxil, and cefoperazone; alongside p-toluenesulfonic acid and related derivatives utilized in the production of doxycycline hydrochloride. Its Active Pharmaceutical Ingredients segment manufactures pharmaceutical-grade bulk substances across diverse therapeutic categories, including local anesthetics such as lidocaine hydrochloride, lidocaine base, and ropivacaine hydrochloride; anti-infectives and respiratory antibiotics such as moxifloxacin hydrochloride and gatifloxacin; proton pump inhibitors and gastrointestinal treatments such as esomeprazole sodium, esomeprazole magnesium, and omeprazole; antigout and cardiovascular therapies such as febuxostat and clopidogrel bisulfate; antidiabetic agents including vildagliptin; urological treatments including tadalafil; and antihistamines and nasal decongestants including chlorpheniramine maleate and naphazoline hydrochloride. In addition, the company provides customized CDMO solutions encompassing process optimization, route verification, analytical method development, and commercial-scale toll manufacturing. The company distributes its products domestically across China and exports to international markets including Europe, the United States, India, Japan, and other Asia-Pacific regions, supported by European Certificates of Suitability (CEP), U.S. FDA Drug Master File (DMF) filings, and ISO-certified manufacturing infrastructure. In recent developments, the company changed its corporate name from Henan Newland Pharmaceutical Co., Ltd. to Newland Pharmaceutical Co., Ltd. to reflect its expanded nationwide and global business footprint. Under its vertically integrated strategy advancing from intermediates toward bulk APIs and finished dosages, the company completed and brought into operation its 120-ton annual capacity active pharmaceutical ingredient production facility and intelligent specialty API supply chain project in late 2025. Furthermore, the company expanded its commercialized API portfolio with the regulatory approval of etomidate API, received European CEP certification for moxifloxacin hydrochloride API to accelerate global market penetration, and progressed the development and clinical evaluation of its downstream finished drug pipeline, including oral solid dosage forms such as oseltamivir phosphate capsules and ruxolitinib phosphate tablets.